SMND-309

• CAT Number: I000323
• CAS Number: 1065559-56-9
• Molecular Formula: C18H14O8
• Molecular Weight: 358.30
• Purity: ≥95%
• Synonyms: (E)-2-[6-[(E)-2-carboxyethenyl]-2,3-dihydroxyphenyl]-3-(3,4-dihydroxyphenyl)prop-2-enoic acid
• InChI: InChI=1S/C18H14O8/c19-12-4-1-9(8-14(12)21)7-11(18(25)26)16-10(3-6-15(22)23)2-5-13(20)17(16)24/h1-8,19-21,24H,(H,22,23)(H,25,26)/b6-3+,11-7+
• InChIKey: OAHRXWZJURTMHG-ACIWFXKJSA-N
• SMILES: C1=CC(=C(C=C1C=C(C2=C(C=CC(=C2O)O)C=CC(=O)O)C(=O)O)O)O

SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats[1][2].
SMND-309 (2.5-10 mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue. SMND-309 also decreases the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment reduces the liver damage and the liver fibrosis grade. SMND-309 treatment powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver[1].

Reference

[1]. Hou J, Tian J, Jiang W, Gao Y, Fu F.
Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis.
Eur J Pharmacol. 2011 Jan 10;650(1):390-5.
 [Content Brief]

[2]. Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J.
Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats.
Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23.
 [Content Brief]

[3]. Wang Y, Zhang J, Han M, et al. SMND-309 promotes neuron survival through the activation of the PI3K/Akt/CREB-signalling pathway. Pharm Biol. 2016;54(10):1982-1990.
 [Content Brief]